(ADINSERTER AMP)
Thursday, September 29, 2022
HomePediatrics Dentistryp53 null phenotype is a “positive result” in urothelial carcinoma in situ

p53 null phenotype is a “positive result” in urothelial carcinoma in situ


  • Levine, A. J., Momand, J. & Finlay, C. A. The p53 tumour suppressor gene. Nature 351, 453–456 (1991).

    CAS 
    Article 

    Google Scholar
     

  • Iggo, R., Gatter, K., Bartek, J., Lane, D. & Harris, A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335, 675–679 (1990).

    CAS 
    Article 

    Google Scholar
     

  • Lohmann, D., Ruhri, C., Schmitt, M., Graeff, H. & Höfler, H. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives. Diagn. Mol. Pathol. 2, 36–41 (1993).

    CAS 
    Article 

    Google Scholar
     

  • Sidransky, D. et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252, 706–709 (1991).

    CAS 
    Article 

    Google Scholar
     

  • Esrig, D. et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol. 143, 1389–1397 (1993).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kelsey, K. T. et al. A population-based study of immunohistochemical detection of p53 alteration in bladder cancer. Br. J. Cancer 90, 1572–1576 (2004).

    CAS 
    Article 

    Google Scholar
     

  • Kuczyk, M. A. et al. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur. J. Cancer 31A, 2243–2247 (1995).

    CAS 
    Article 

    Google Scholar
     

  • Serth, J. et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br. J. Cancer 71, 201–205 (1995).

    CAS 
    Article 

    Google Scholar
     

  • Amin, M. B., Trpkov, K., Lopez-Beltran, A. & Grignon, D., Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am. J. Surg. Pathol. 38, e20–e34 (2014).

    Article 

    Google Scholar
     

  • Köbel, M. et al. Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility. Int. J. Gynecol. Pathol. 38, S123–S131 (2019).

    Article 

    Google Scholar
     

  • McCluggage, W. G., Soslow, R. A. & Gilks, C. B. Patterns of p53 immunoreactivity in endometrial carcinomas: ‘all or nothing’ staining is of importance. Histopathology 59, 786–788 (2011).

    Article 

    Google Scholar
     

  • Hodgson, A., Xu, B. & Downes, M. R. p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant. Histopathology 71, 296–304 (2017).

    Article 

    Google Scholar
     

  • Neal, D. J., Amin, M. B. & Smith, S. C. CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia. Diagn. Pathol. 15, 61 (2020).

    CAS 
    Article 

    Google Scholar
     

  • Nguyen, J. K., Przybycin, C. G., McKenney, J. K. & Magi-Galluzzi, C. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap. Hum. Pathol. 98, 81–88 (2020).

    CAS 
    Article 

    Google Scholar
     

  • Sangoi, A. R., Chan, E., Stohr, B. A. & Kunju, L. P. Invasive plasmacytoid urothelial carcinoma: a comparative study of E-cadherin and P120 catenin. Hum. Pathol. 102, 54–59 (2020).

    CAS 
    Article 

    Google Scholar
     

  • McKenney, J. K., Gomez, J. A., Desai, S., Lee, M. W. & Amin, M. B. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am. J. Surg. Pathol. 25, 356–362 (2001).

    CAS 
    Article 

    Google Scholar
     

  • Chan, E., Garg, K. & Stohr, B. A. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer. Mod. Pathol. 33, 1802–1810 (2020).

    CAS 
    Article 

    Google Scholar
     

  • Arias-Stella, J. A. 3rd, Shah, A. B., Gupta, N. S. & Williamson, S. R. CK20 and p53 immunohistochemical staining patterns in urinary bladder specimens with Equivocal Atypia. Arch. Pathol. Lab. Med. 142, 64–69 (2018).

    CAS 
    Article 

    Google Scholar
     

  • Aron, M. et al. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. Am. J. Surg. Pathol. 37, 1815–1823 (2013).

    Article 

    Google Scholar
     

  • Lawless, M. E., Tretiakova, M. S., True, L. D. & Vakar-Lopez, F. Flat Urothelial Lesions with Atypia: interobserver concordance and added value of immunohistochemical profiling. Appl. Immunohistochem. Mol. Morphol. 26, 180–185 (2018).

    Article 

    Google Scholar
     

  • Mallofré, C., Castillo, M., Morente, V. & Solé, M. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod. Pathol. 16, 187–191 (2003).

    Article 

    Google Scholar
     

  • McKenney, J. K., Desai, S., Cohen, C. & Amin, M. B. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am. J. Surg. Pathol. 25, 1074–1078 (2001).

    CAS 
    Article 

    Google Scholar
     

  • Oliva, E. et al. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases. Hum. Pathol. 44, 860–866 (2013).

    CAS 
    Article 

    Google Scholar
     

  • Pederzoli, F. et al. Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical. Hum. Pathol. 90, 1–7 (2019).

    Article 

    Google Scholar
     

  • Sun, W., Zhang, P. L. & Herrera, G. A. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder. Appl. Immunohistochem. Mol. Morphol. 10, 327–331 (2002).

    CAS 
    PubMed 

    Google Scholar
     

  • Yildiz, I. Z. et al. Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies. Diagn. Pathol. 4, 35 (2009).

    Article 

    Google Scholar
     

  • Köbel, M. et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J. Pathol. 222, 191–198 (2010).

    Article 

    Google Scholar
     

  • Hartmann, A. et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 62, 809–818 (2002).

    CAS 
    PubMed 

    Google Scholar
     

  • Sarkis, A. S. et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol. 152, 388–392 (1994).

    CAS 
    Article 

    Google Scholar
     

  • Schmitz-Dräger, B. J. et al. P53 accumulation in precursor lesions and early stages of bladder cancer. World J. Urol. 12, 79–83 (1994).

    Article 

    Google Scholar
     

  • Akhtar, M. et al. Urothelial Carcinoma In Situ (CIS): new insights. Adv. Anat. Pathol. 26, 313–319 (2019).

    CAS 
    Article 

    Google Scholar
     

  • Amin, M. B. et al. The Genitourinary Pathology Society update on classification and grading of flat and papillary urothelial neoplasia with new reporting recommendations and approach to lesions with mixed and early patterns of Neoplasia. Adv. Anat. Pathol. 28, 179–195 (2021).

    Article 

    Google Scholar
     

  • Schultheis, A. M. et al. TP53 mutational spectrum in Endometrioid and Serous Endometrial Cancers. Int J. Gynecol Pathol. 35, 289–300 (2016).

    CAS 
    Article 

    Google Scholar
     

  • RELATED ARTICLES

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    Most Popular

    Recent Comments